Egrifta Quality Of Life Deciding Factor In Advisory Panel's Recommendation

Improving patients' quality of life seemed to be more important than an unproven cardiovascular benefit in an FDA advisory panel's unanimous vote to recommend approval of Theratechnologies' Egrifta (tesamorelin), indicated for reduction of visceral adipose tissue in HIV patients receiving antiretroviral therapy